Published in
American Society of Hematology, Blood, 13(130), p. 1578-1584
DOI: 10.1182/blood-2017-05-783415
Links
Tools
Delineation of the timing of second-line therapy post–autologous stem cell transplant in patients with AL amyloidosis
Journal article published in 2017 by
Yi L. Hwa,
Rahma Warsame 
,
Morie A. Gertz ,
Francis K. Buadi ,
Martha Q. Lacy,
Shaji K. Kumar,
David Dingli,
Steve R. Zeldenrust,
Nelson Leung,
Susanne R. Hayman,
Prashant Kapoor,
Wilson I. Gonsalves,
Taxiarchis V. Kourelis,
Stephen Russell,
Ronald S. Go
and other authors.
,
Morie A. Gertz ,
Francis K. Buadi ,
Martha Q. Lacy,
Shaji K. Kumar,
David Dingli,
Steve R. Zeldenrust,
Nelson Leung,
Susanne R. Hayman,
Prashant Kapoor,
Wilson I. Gonsalves,
Taxiarchis V. Kourelis,
Stephen Russell,
Ronald S. Go
and other authors.
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points Organ progression at second-line therapy predicated inferior survival. Patients relapsing from >VGPR had a longer time to develop organ progression.